About Me
From a conjecture that cellular specificity during embryogenesis could be predicted based on diffusion very early on in my study to the recognition of the significance of CAR T Cell therapy, discovery has been a repeated highlight of my research. Written in a letter of reference for me, Dr. Duval, a then adjunct professor at the University of New Haven, “Scott has developed the ability to be extremely creative and to enunciate hypotheses that could potentially translate into medical applications.”
I spent years researching and working in de novo drug discovery in immunology and targeted cancer therapies. I’ve edited manuscripts that were published by Pfizer, and I’ve written on therapeutics in clinical trials, including an adverse event involving an on-target, off-tissue CAR T Cell construct.
Because the work I do involves proprietary information, I cannot provide details about previous engagements. I will instead, here, focus on my own research as it is how I came to do the work I do.
Novel Approach, Novel Therapeutic
The goal of my research was to develop a therapeutic capable of targeting intracellular oncoantigens. Lacking a lab, I used published results to select the elements to construct a chimeric protein capable of crossing the cell membrane and releasing a constitutively active caspase upon mAb ligand binding.
This novel approach to drug discovery resulted in my paper being published in Elsevier’s Drug Discovery Today. Commentary on my paper generated during the peer review process as well as post-publication review by academic and pharmaceutical leaders showed my proposed therapeutic to be novel and likely effective.
Identifying Significant Research
I have the ability to draw upon a broad and deep, multidisciplinary knowledge in the life sciences that allows me to develop an understanding of any pathology. When coupled with my ability to read deeply into the literature, it allows me to consistently find supportive, clinically significant, research at every stage of discovery.
For example, during my research in the etiology of osteoarthritis (OA) I was exploring my conjecture that OA was caused by long-term, repeated, microinjury and could be mitigated by the clearing of wear particles. I found research describing the small molecule Kartogenin that is being used with lavash as an adjuvant. In animal models it has been shown to induce chondrogenesis resulting in reconstitution of articulating cartilage and healthy bone restoration.
